Retrovir™
Active ingredients: Zidovudine
Consumer medicine information
Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.
Listen to the audio transcription of the CMI leaflet.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
Retrovir is indicated for: . Treatment of adult patients with severe symptomatic human immunodeficiency virus infection (AIDS or advanced AIDS related complex); . Treatment of other HIV-positive adult patients with less than 500 CD4 cells/mm3. Notes: (1) The limited available data currently support the extended use of Retrovir (Indication 2 above). (2) The optimal dosage for these indications has not been established. . Combination therapy in advanced HIV infection. The addition of HIVID (Zalcitabine) may be considered for the management of adult patients with advanced HIV infection and CD4 + cell counts less than or equal to 200/mm3, who have received Retrovir monotherapy for less than 12 months. Retrovir monotherapy is still indicated as initial therapy for adult patients with HIV infection who fulfil the approved indications. NEW INDICATIONS APPROVED 7TH FEBRUARY 1997: Retrovir (zidovudine) is indicated for the treatment of HIV infection, alone and in combination with other antiretroviral therapies. The optimum dosage for this indication has not been established.
Source: ARTG
Storage conditions
- Shelf lifetime is 5 Years
- Store below 30 degrees Celsius
- Protect from Light
Source: ARTG
How to use this medicine
Non-composite pack
This medicine contains one component only.
Component
- Capsule
- Oral
- Opaque white cap and body coded GSYJU
Source: ARTG
Images

Images © Medicines Information Pty Ltd.
Do I need a prescription?
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.
- 100 capsules
Source: ARTG
Is this medicine subsidised?
This medicine was verified as available on the Pharmaceutical Benefits Scheme (PBS) on 1 August 2026, under PBS item code 10266H (Opens in new tab). Ask your pharmacist or doctor about your eligibility
Source: PBS
Pregnant or planning a pregnancy?
For the active ingredient: Zidovudine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Source: AHT
Reporting side effects
If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).
You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)
Source: ARTG
Data sources
- Australian Health Thesaurus (AHT) (Opens in new tab) – Last updated on 3 August 2026
- Australian Medicines Terminology (AMT) (Opens in new tab) – Last updated on 3 August 2026
- Australian Register of Therapeutic Goods (ARTG) (Opens in new tab) – Last updated on 3 August 2026
- Pharmaceutical Benefits Scheme (PBS) (Opens in new tab) – Last updated on 3 August 2026
- Medicines Information Pty Ltd (Opens in new tab) – Last updated on 4 March 2026
Disclaimer
Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).
Symptom Checker
Worried about your health?
Select a symptom, answer some questions, get advice